GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists

GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists are associated with body weight in humans (12.17 ± 10.64 kg reduction; 11.71% ± 9.40% reduction from reported baseline).

“The mean observed reduction in body weight from treatment initiation to the study assessment was 12.17 ± 10.64 kg”

HumansObesity or glucose metabolism disorder; retrospectively reported baseline weight66.7% womensn = 531

Real-World Anthropometric Outcomes, Safety, and Use Patterns of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity and Glucose Metabolism Disorder: A Nationwide Multicentre Community Pharmacy Study

Healthcare (Basel, Switzerland)·Oct 8, 2026